Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611 5/11/2025

4,880 USD (+1,04%)

(+1,04%) 5/11/2025

Grafiek Alvotech

Grafiek Alvotech

1 dag1d 1,04%
1 week1w -37,76%
1 maand1m -43,12%
3 maanden3m -42,32%
6 maanden6m -38,77%
1 jaar1j -61,73%
5 jaar5j -56,39%

Alvotech in het nieuws

Toon enkel gratis nieuws

4 november 2025 · Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update · Persbericht

2 november 2025 · Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 · Persbericht

22 oktober 2025 · Alvotech Announces Changes in Global Business Development and Commercial Operations Team · Persbericht

6 oktober 2025 · European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency · Persbericht

22 september 2025 · European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva® · Persbericht

22 september 2025 · European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner · Persbericht

19 september 2025 · Alvotech Announces Marketing Approval in Japan of Three New Biosimilars · Persbericht

4 september 2025 · Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York · Persbericht

21 augustus 2025 · Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® · Persbericht

20 augustus 2025 · Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe